|
Tender for Procurement Of Anticancer Drugs For The Year 2026-27 , Abiraterone Acetate Tab Ip 250 Mg , Afatinib Tab 30 Mg , Bendamustine Inj Ip 100 Mg , Bortezomib Inj Ip 2 Mg , Capecitabine Tab Ip 500 Mg , Cytarabine Inj Ip/Bp 100 Mg , Etoposide Cap Ip 50 Mg , Etoposide Inj Ip 100 Mg , Exemestane Tab Ip 25 Mg , Ferric Carboxymaltose Inj 1 Gm/20 Ml , Filgrastim Inj Ip 300 Mcg , Fulvestrant Inj 250 Mg , Gefitinib Tab Ip 250 Mg , L.Asparaginase Inj 5000 Iu , Lapatinib Tab Ip 250 Mg , Letrozole Tab Ip/Usp 2.5 Mg , Paclitaxel Nanoparticle Inj 100 Mg , Pazopanib Tab 400 Mg , Pegfilgrastim Inj 6 Mg , Sunitinib Cap 12.5 Mg , Bevacizumab Inj 100 Mg , Bevacizumab Inj 400 Mg , Carboplatin Inj Ip 150 Mg , Carboplatin Inj Ip 450 Mg , Cisplatin Inj Ip 10 Mg , Cisplatin Inj Ip 50 Mg , Dasatinib Tab 20 Mg , Dasatinib Tab 50 Mg , Docetaxel Inj Ip 20 Mg , Docetaxel Inj Ip 80 Mg , Docetaxel Inj Ip 120 Mg , Doxorubicin Inj (Lyophilised) Ip 10 Mg , Doxorubicin Inj (Lyophilised) Ip 50 Mg , Epirubicin Inj Ip 10 Mg , Epirubicin Inj Ip 50 Mg , Erlotinib Tab Ip 100 Mg , Erlotinib Tab Ip 150 Mg , Gemcitabine Inj Ip 200 Mg , Gemcitabine Inj Ip 1 Gm , Ifosfamide With Mesna Inj 1 Gm , Ifosfamide With Mesna Inj 2 Gm , Imatinib Tab Ip 100 Mg , Imatinib Tab Ip 400 Mg , Irinotecan Inj Ip 40 Mg , Irinotecan Inj Ip 100 Mg , Lenalidomide Cap 10 Mg , Lenalidomide Cap 5Mg , Leuprolide Acetate Inj 3.75 Mg , Leuprolide Acetate Inj 11.25 Mg , Leuprolide Acetate Inj 22.5 Mg , Methotrexate Inj Ip 50 Mg , Methotrexate Inj Ip 500 Mg , Nilotinib Cap 200 Mg , Nilotinib Cap 150 Mg , Oxaliplatin Inj Ip 50 Mg , Oxaliplatin Inj Ip 100 Mg , Paclitaxel Inj Ip 30 Mg , Paclitaxel Inj Ip With Codon Set 100 Mg , Paclitaxel Inj Ip With Codon Set 260 Mg , Pemetrexed Inj Ip 100 Mg , Pemetrexed Inj Ip 500 Mg , Rituximab Inj 100 Mg , Rituximab Inj 500 Mg , Temozolomide Cap Ip 100 Mg , Temozolomide Cap Ip 250 Mg , Trastuzumab Inj 150 Mg , Trastuzumab Inj 440 Mg
|
